Results 51 to 60 of about 111,950 (304)

A systematic review on the association between ovarian and prostate cancer with BRCA1 and BRCA2 gene

Сибирский онкологический журнал, 2023
Background. BRCA1 and BRCA2 were discussed as the basis of inherited adenocarcinoma and breast and ovarian malignancy. Ovarian cancer is uncommon in women below 40 years of age, and prostate cancer mainly occurs in older men cause 90 % in those above ...
Sarpparajan Chitra Veena, Mohammed Vajagathali, Veerabathiran Ramakrishnan   +2 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

ОСОБЕННОСТИ ЭКСПРЕССИИ РЕЦЕПТОРОВ ЭСТРОГЕНОВ, ПРОГЕСТЕРОНА И АНДРОГЕНОВ ПРИ НАСЛЕДСТВЕННЫХ И СПОРАДИЧЕСКИХ ОВАРИАЛЬНЫХ КАРЦИНОМАХ

Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2022
Введение. Овариальные карциномы – сложное гетерогенное заболевание с разнообразием клинико-морфологических форм. В большинстве случаев опухоли яичников экспрессируют эстрогеновые (РЭ), прогестероновые (РП) или андрогеновые (РА) рецепторы, но, в отличие ...
А. L. Savаnevich, A. V. Shulha, A. V. Kapytski   +2 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Transcriptional Autoregulation by BRCA1 [PDF]

Cancer Research, 2010
Abstract The BRCA1 gene product plays numerous roles in regulating genome integrity. Its role in assembling supermolecular complexes in response to DNA damage has been extensively studied; however, much less is understood about its role as a transcriptional coregulator. Loss or mutation is associated with hereditary breast and ovarian
de Siervi, Adriana, de Luca, Paola, Byun, Jung S., Di, Li Jun, Fufa, Temesgen, Haggerty, Cynthia M., Vazquez, Elba Susana, Moiola, Cristian Pablo, Longo, Dan L., Gardner, Kevin   +9 more
openaire   +3 more sources

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1 [PDF]

Oncogene, 2001
Unregulated expression of wild-type BRCA1 (wtBRCA1) confers an altered phenotype in cultured human prostate cancer cells, characterized by chemosensitivity, susceptibility to apoptosis, decreased DNA repair activity, and alterations of key cell regulatory proteins.
S, Fan, R, Yuan, Y X, Ma, Q, Meng, I D, Goldberg, E M, Rosen   +5 more
openaire   +2 more sources

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Genetic Epidemiology of BRCA1 [PDF]

Cancer Biology & Therapy, 2004
Since the identification of the BRCA1 gene 10 years ago much has been learned about the role of the BRCA1 protein in cancer development. In particular, genetic and epidemiological approaches have informed about the spectrum of mutations that occur in the gene and the prevalence, penetrance, and phenotype associated with these mutations in various ...
openaire   +2 more sources

Population testing for cancer predisposing BRCA1/BRCA2 mutations [PDF]

, 2014
Background: Technological advances raise the possibility of systematic population-based genetic testing for cancer-predisposing mutations, but it is uncertain whether benefits outweigh disadvantages.
Wardle, J
core